These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37675498)

  • 1. The role of upadacitinib for the treatment of axial spondyloarthritis.
    George N; Liew JW; Dubreuil M
    Immunotherapy; 2023 Oct; 15(15):1227-1237. PubMed ID: 37675498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Deodhar A; Van den Bosch F; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Blanco R; Duan Y; Li Y; Pangan AL; Wung P; Song IH
    Lancet; 2022 Jul; 400(10349):369-379. PubMed ID: 35908570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety.
    Tang H; Liu X; Zhao J; Tang Z; Zheng Z; Bai W
    Clin Rheumatol; 2024 Aug; 43(8):2391-2402. PubMed ID: 38874670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
    Fukui S; Kawaai S; Sawada H; Kishimoto M
    Expert Rev Clin Immunol; 2024 Feb; 20(2):141-153. PubMed ID: 37955181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
    van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
    Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
    Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib: Mechanism of action, clinical, and translational science.
    Mohamed MF; Bhatnagar S; Parmentier JM; Nakasato P; Wung P
    Clin Transl Sci; 2024 Jan; 17(1):e13688. PubMed ID: 37984057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
    Mysler E; Lizarraga A
    Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
    Law CCY; Kayal M; Mehandru S; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
    Akkoc N; Khan MA
    Curr Rheumatol Rep; 2021 Apr; 23(6):34. PubMed ID: 33909185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.
    Bhatnagar S; Eckert D; Stodtmann S; Song IH; Wung P; Liu W; Mohamed MF
    Clin Transl Sci; 2024 Feb; 17(2):e13733. PubMed ID: 38344875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.
    Paroli M; Caccavale R; Paroli MP; Spadea L; Accapezzato D
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors: a future all-rounder in axial spondyloarthritis?
    Huang JX; Wei JC
    Immunotherapy; 2023 Oct; 15(15):1195-1198. PubMed ID: 37718695
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
    Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upadacitinib in Crohn's disease.
    Dignass A; Esters P; Flauaus C
    Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.